Trial Profile

A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 26 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 800 TCR (Primary) ; Cyclophosphamide; Fludarabine
Indications Renal cell carcinoma
Focus Adverse reactions; First in man

Most Recent Events

28 Apr 2026 Planned End Date changed from 3 Mar 2026 to 3 Mar 2029.
03 Dec 2024 Number of treatment arms have been increased from 1 to 4 by the addition of separate arms for separate dose levels.
03 Dec 2024 Planned End Date changed from 31 Dec 2032 to 3 Mar 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com